TY - JOUR AU - Zhao, Y. AU - Adjei, A. A. PY - 2014 DA - 2014// TI - The clinical development of MEK inhibitors JO - Nat Rev Clin Oncol VL - 11 UR - https://doi.org/10.1038/nrclinonc.2014.83 DO - 10.1038/nrclinonc.2014.83 ID - Zhao2014 ER - TY - JOUR AU - Davies, H. AU - Bignell, G. R. AU - Cox, C. AU - Stephens, P. AU - Edkins, S. AU - Clegg, S. PY - 2002 DA - 2002// TI - Mutations of the BRAF gene in human cancer JO - Nature VL - 417 UR - https://doi.org/10.1038/nature00766 DO - 10.1038/nature00766 ID - Davies2002 ER - TY - JOUR AU - Curtin, J. A. AU - Fridlyand, J. AU - Kageshita, T. AU - Patel, H. N. AU - Busam, K. J. AU - Kutzner, H. PY - 2005 DA - 2005// TI - Distinct sets of genetic alterations in melanoma JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa050092 DO - 10.1056/NEJMoa050092 ID - Curtin2005 ER - TY - JOUR AU - Ribas, A. AU - Gonzalez, R. AU - Pavlick, A. AU - Hamid, O. AU - Gajewski, T. AU - Daud, A. PY - 2014 DA - 2014// TI - Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70301-8 DO - 10.1016/S1470-2045(14)70301-8 ID - Ribas2014 ER - TY - JOUR AU - Long, G. V. AU - Stroyakovskiy, D. AU - Gogas, H. AU - Levchenko, E. AU - Braud, F. AU - Larkin, J. PY - 2014 DA - 2014// TI - Combined BRAF and MEK Inhibition versus BRAF inhibition alone in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406037 DO - 10.1056/NEJMoa1406037 ID - Long2014 ER - TY - JOUR AU - Larkin, J. AU - Ascierto, P. A. AU - Dréno, B. AU - Atkinson, V. AU - Liszkay, G. AU - Maio, M. PY - 2014 DA - 2014// TI - Combined vemurafenib and cobimetinib in BRAF-mutated melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1408868 DO - 10.1056/NEJMoa1408868 ID - Larkin2014 ER - TY - STD TI - Atkinson V, Larkin J, McArthur GA, Ribas A, Ascierto PA, Liszkay G, et al. Improved overall survival (OS) with cobimetinib (COBI)+ vemurafenib (V) in advanced BRAF-mutated melanoma and biomarker correlates of efficacy. 12th International Congress of the Society for Melanoma Research, November 18-21, San Francisco, CA; 2015. http://www.roche.com/dam/jcr:b7f64a44-c724-4b2b-8976-9f33954f1492/en/med-cor-2015-11-23-e.pdf. UR - http://www.roche.com/dam/jcr:b7f64a44-c724-4b2b-8976-9f33954f1492/en/med-cor-2015-11-23-e.pdf ID - ref7 ER - TY - JOUR AU - Infante, J. R. AU - Fecher, L. A. AU - Falchook, G. S. AU - Nallapareddy, S. AU - Gordon, M. S. AU - DeMarini, D. J. PY - 2012 DA - 2012// TI - Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70270-X DO - 10.1016/S1470-2045(12)70270-X ID - Infante2012 ER - TY - JOUR AU - Urner-Bloch, U. AU - Urner, M. AU - Stieger, P. AU - Galliker, N. AU - Winterton, N. AU - Zubel, A. PY - 2014 DA - 2014// TI - Transient MEK inhibitor-associated retinopathy in metastatic melanoma JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu169 DO - 10.1093/annonc/mdu169 ID - Urner-Bloch2014 ER - TY - JOUR AU - Weekes, C. D. AU - Hoff, D. D. AU - Adjei, A. A. AU - Leffingwell, D. P. AU - Eckhardt, S. G. AU - Gore, L. PY - 2013 DA - 2013// TI - Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-3529 DO - 10.1158/1078-0432.CCR-12-3529 ID - Weekes2013 ER - TY - JOUR AU - Noll, R. AU - Leijen, S. AU - Neuteboom, G. H. G. AU - Beijnen, J. H. AU - Schellens, J. H. M. PY - 2013 DA - 2013// TI - Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities JO - Cancer Treat Rev VL - 39 UR - https://doi.org/10.1016/j.ctrv.2013.01.003 DO - 10.1016/j.ctrv.2013.01.003 ID - Noll2013 ER - TY - JOUR AU - McCannel, T. A. AU - Chmielowski, B. AU - Finn, R. S. AU - Goldman, J. AU - Ribas, A. AU - Wainberg, Z. A. PY - 2014 DA - 2014// TI - Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer JO - JAMA Ophthalmol VL - 132 UR - https://doi.org/10.1001/jamaophthalmol.2014.976 DO - 10.1001/jamaophthalmol.2014.976 ID - McCannel2014 ER - TY - JOUR AU - Houde, N. AU - Faivre, S. J. AU - Awada, A. AU - Raymond, E. AU - Italiano, A. AU - Besse-Hammer, T. PY - 2011 DA - 2011// TI - Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/jco.2011.29.15_suppl.3019 DO - 10.1200/jco.2011.29.15_suppl.3019 ID - Houde2011 ER - TY - JOUR AU - Schoenberger, S. D. AU - Kim, S. J. PY - 2013 DA - 2013// TI - Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma JO - Case Rep Ophthalmol Med VL - 2013 ID - Schoenberger2013 ER - TY - JOUR AU - Nicholson, B. AU - Noble, J. AU - Forooghian, F. AU - Meyerle, C. PY - 2013 DA - 2013// TI - Central serous chorioretinopathy: update on pathophysiology and treatment JO - Surv Ophthalmol VL - 58 UR - https://doi.org/10.1016/j.survophthal.2012.07.004 DO - 10.1016/j.survophthal.2012.07.004 ID - Nicholson2013 ER - TY - JOUR AU - Duncan, K. E. AU - Chang, L. Y. AU - Patronas, M. PY - 2015 DA - 2015// TI - MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity JO - Eye (Lond) VL - 29 UR - https://doi.org/10.1038/eye.2015.82 DO - 10.1038/eye.2015.82 ID - Duncan2015 ER - TY - JOUR AU - Long, G. V. AU - Stroyakovskiy, D. AU - Gogas, H. AU - Levchenko, E. AU - deBraud, F. AU - Larkin, J. PY - 2015 DA - 2015// TI - Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial JO - Lancet VL - 386 UR - https://doi.org/10.1016/S0140-6736(15)60898-4 DO - 10.1016/S0140-6736(15)60898-4 ID - Long2015 ER - TY - JOUR AU - Robert, C. AU - Karaszewska, B. AU - Schachter, J. AU - Rutkowski, P. AU - Mackiewicz, A. AU - Stroiakovski, D. PY - 2015 DA - 2015// TI - Improved overall survival in melanoma with combined dabrafenib and trametinib JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412690 DO - 10.1056/NEJMoa1412690 ID - Robert2015 ER - TY - JOUR AU - Runkle, E. A. AU - Antonetti, D. A. PY - 2011 DA - 2011// TI - The blood-retinal barrier: structure and functional significance JO - Methods Mol Biol VL - 686 UR - https://doi.org/10.1007/978-1-60761-938-3_5 DO - 10.1007/978-1-60761-938-3_5 ID - Runkle2011 ER - TY - JOUR AU - Jiang, Q. AU - Cao, C. AU - Lu, S. AU - Kivlin, R. AU - Wallin, B. AU - Chu, W. PY - 2009 DA - 2009// TI - MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells JO - Int J Mol Med VL - 23 UR - https://doi.org/10.3892/ijmm_00000191 DO - 10.3892/ijmm_00000191 ID - Jiang2009 ER -